Cytophenix FloCAST
Rapid Antimicrobial Susceptibility Testing

4-hour same-shift AST results. 48–72 hours faster than current methods.

Why It Matters

Why Rapid Antimicrobial Susceptibility Testing (AST) Matters

Faster AST transforms patient care for patients with life-threatening infections.

4-Hour AST Results

4-Hour AST Results

Delivers AST results for doctors to optimize antimicrobial therapy in the same shift as the positive blood culture.

Expedite Answers to Bedside

Expedite Answers to Bedside

Accelerate clinical confidence from the clinical microbiology laboratory to the patient care team.

Mitigate Sepsis Mortality Risk

Mitigate Sepsis Mortality Risk

Reduces the deadly delays in effective antimicrobial therapy that raise mortality by up to 7.6% per hour. (Kumar et al.)1 (Liu et al.)2

Reduce Adverse Events

Reduce Adverse Events

Enables targeted therapy that reduces risks of extended broad-spectrum antimicrobial therapy, including kidney damage, C. difficile infection, and blindness.

Gram-negative MDRO AST results showing antimicrobial susceptibility interpretations for a patientFor Research Use Only (RUO)
Clinical Impact

Improve Clinical Decision Making for Life-Threatening Infections

For patients with serious infections, Cytophenix FloCAST delivers AST in 4 hours same-shift for Gram-negative bacteria and fungi, including the alarming MDRO threat Candida auris.

Patient survival over time: Cytophenix FloCAST AST results available in an earlier window than existing testsReal-world patient trial data using Cytophenix FloCASTHours Since Positive Blood Culture
Reliable Delivery

Expedite Actionable Antimicrobial Answers to the Patient Bedside

An Australia regional hospital study demonstrated mean AST results delivered 35 hours faster than current methods.

Cytophenix FloCAST workflow delivers AST results 48–72 hours faster than legacy methods
Best Practice

Mitigate or Eliminate Risk of the Sepsis Response

Cytophenix FloCAST best aligns laboratory and clinical practice with the requisite urgency of sepsis. It reduces the diagnostic horizon commensurate with the Society of Critical Care Medicine's Surviving Sepsis Campaign Hour-1 Bundle (SEP-1 Bundle).

Rapid AST enables de-escalation same-shift, reducing the risk of adverse events for patients with extended broad-spectrum antimicrobial therapy.

The Technology

How Cytophenix FloCAST Works

Video thumbnail
Antimicrobial Menu

Provisional Antimicrobial Targets for Cytophenix FloCAST

Antibiotics

Ceftazidime / avibactamAmoxicillin / clavulanic acidAztreonamCefepimeCeftazidimeCeftriaxoneCiprofloxacinGentamicinMeropenemTigecyclinePiperacillin / tazobactamTrimethoprim / sulfamethoxazoleAztreonam / avibactamCeftolozane / tazobactamImipenem / cilastatin / relebactamMeropenem / vaborbactamPlazomicinCefiderocol

Antifungals

Fluconazole5-FlucytosineAmphotericin BAnidulafunginCaspofunginIsavuconazoleItraconazoleMicafunginPosaconazoleRezafungin

Is there an antimicrobial that you'd like to see us include on an AST panel? Please share your feedback below.

Share Feedback

Request Full AST Panel Details

Complete the form below to receive additional information on Cytophenix FloCAST antimicrobial panels.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Explore Cytophenix FloCAST